Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Advanced Accelerator Applications","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase III"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"ABX Advanced Biochemical Compounds","pharmaFlowCategory":"D","amount":"$172.0 million","upfrontCash":"$12.0 million","newsHeadline":"Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. of - Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novartis Pluvicto\u2122 Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-Resistant Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Advanced Accelerator Applications","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MHRA Grants Marketing Authorisation for Novartis\u2019 Radioligand Therapy Pluvicto\u00ae (Lutetium (\u00b9\u2077\u2077lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Large molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Advanced Accelerator Applications

    Menu

    Advanced Accelerator Applications

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Advanced Accelerator Applications

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MHRA Grants Marketing Authorisation for Novartis’ Radioligand Therapy Pluvicto® (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britai...

              Details:

              Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) is indicated for the treatment of adult patients with PSMA-positive mCRPC who have been treated with AR pathway inhibition and taxane-based chemotherapy or who are not medically suitable for taxanes.

              Lead Product(s): Lutetium-177 Vipivotide Tetraxetan

              Therapeutic Area: Oncology Product Name: Pluvicto

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advanced Accelerator Applications

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Otsuka Subsidiary to Receive Payment and Royalties from Approval in U.S. of - Out-licensed by ABX in Germany, an indirectly-owned subsidiary of Otsuka Pharmaceutical

              Details:

              Advanced Accelerator Applications (AAA) and Endocyte, Inc., both Novartis companies, successfully completed full-scale development of Pluvicto and also received Breakthrough Therapy designation from the U.S. FDA last year.

              Lead Product(s): Lutetium-177 Vipivotide Tetraxetan

              Therapeutic Area: Oncology Product Name: Pluvicto

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: ABX Advanced Biochemical Compounds

              Deal Size: $172.0 million Upfront Cash: $12.0 million

              Deal Type: Agreement March 29, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advanced Accelerator Applications

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Novartis Pluvicto™ Approved by FDA as First Targeted Radioligand Therapy for Treatment of Progressive, PSMA-positive Metastatic Castration-Resistant Prostate Cancer

              Details:

              FDA approval was based on VISION trial, where patients with pre-treated PSMA-positive mCRPC who received Pluvicto plus standard of care had a statistically significant reduction in risk of death1; both alternate primary endpoints of OS and radiographic PFS were met.

              Lead Product(s): Lutetium-177 Vipivotide Tetraxetan

              Therapeutic Area: Oncology Product Name: Pluvicto

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Novartis Pharmaceuticals Corporation

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 23, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Advanced Accelerator Applications

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              ITM expands PSMA-617 supply agreement for no-carrier-added Lutetium-177

              Details:

              ITM will provide Endocyte with supply of n.c.a 177Lu for its investigational 177Lu-PSMA-617 radioligand therapy for patients with metastatic castration-resistant prostate cancer.

              Lead Product(s): Lutetium-177 Vipivotide Tetraxetan

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Recipient: ITM

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement March 02, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY